Drug Profile
Glatiramer acetate liposomal - Pharmsynthez/Xenetic Biosciences
Alternative Names: Liposomal multiple sclerosis vaccine - Pharmsynthez; MyeloXenLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Pharmsynthez
- Developer Pharmsynthez; Xenetic Biosciences
- Class Peptides; Polymers
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
- 12 Feb 2016 Discontinued - Preclinical for Multiple sclerosis in Israel (SC)
- 21 Nov 2014 Pharmsynthez completes dosing in a phase II trial in Multiple sclerosis (Second-line therapy or greater) in Russia